Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

TIME magazine has released the list of the 100 Most Influential People of 2025 and Reshma Kewalramani, Indian-origin CEO, is ...

From US president Donald Trump to Tesla CEO Elon Musk, Time Magazine's 100 Most Influential People of 2025 list included some ...

The most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...

Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...

The Global Synthetic Biology Market is valued at USD 16.94 Billion in 2024 and is projected to reach a value of USD 167.98 ...

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Certara’s AI strategy and FDA-aligned offerings fuel growth across drug discovery and trials, with expanding margins. Read ...

Fastenal on Friday reported first-quarter 2025 revenue of $1.959 billion, a 3.4% year-over-year increase and slightly above ...

DNA nanotechnology is a branch of nanotechnology concerned with the design, study and application of synthetic structures based on DNA. DNA nanotechnology takes advantage of the physical and ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...